About Bio Investor Forum
A national investor forum to explore investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2014. Because our mission is to support industry-wide success, we strive to present a broad and unbiased view of investment opportunities.
The BIO Investor Forum delivers a rich program that features corporate presentations and panel debates on the sweet spots and growth challenges facing the industry. The BIO Investor Forum features:
Public and venture-stage company presentations.
Expert-led workshops on the latest market and investment opportunities with emphasis on drug and technology development.
One-on-one investor meetings.
Premier opportunity to network with industry executives and investors focused exclusively on life sciences.
Private equity and public investors, research analysts, and industry executives focused on investment and business development opportunities in the life sciences.
Why Investors Attend
Hear from and meet with executives at the top life sciences growth companies.
Evaluate fresh investment opportunities including compatible, complementary and competitive companies.
Benefit from candid panel discussions with leading clinical experts and investigators with insights on pipeline research and clinical practice.
Get a ‘big picture’ overview of the industry and the issues affecting product innovation, capitalization, and commercialization
Why Companies Attend
Meet one-on-one with new and current investors, analysts, and partnering companies.
Get the pulse on the latest life sciences investment trends from sophisticated investment and company executives.
Showcase your company story in presentations to qualified investors.
Network with peers, investors and potential partners.
Sentiment: Strong Buy
From the Intrexon filing (page 97)
"Effective January 6, 2011, we entered into an ECC with ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), or ZIOPHARM, a publicly traded small molecule late-stage oncology drug development company, to develop and commercialize therapeutics in the field of cancer treatment in humans. The lead product candidates of this ECC include DC-IL-12 and Ad-IL-12 for the treatment of melanoma and breast cancer. DC-IL-12 has completed a Phase I human clinical trial to establish the drug’s safety. Ad-IL-12 is currently in multiple Phase II human clinical studies.
Both of these programs are focused on the regulatable expression of Interleukin-12 (IL-12). IL-12 is a naturally occurring anticancer cytokine central to the initiation and regulation of cellular anti-cancer immune responses. Until now, the use of IL-12 as a cancer therapeutic has been limited due to significant toxicities observed with its systemic use at doses high enough to exhibit a therapeutic effect.
Both of the IL-12 programs of this ECC deliver genetic vectors coding for the IL-12 gene directly to tumors. DC-IL-12 uses a patient’s own dendritic cells as the delivery vehicle, whereas Ad-IL-12 uses adenovirus. Once the vector is delivered intratumorally, it is controlled by Intrexon’s proprietary on/off biologic switch called the RheoSwitch Therapeutic System, or RTS. RTS maintains the gene program in an inactive state within a cell, until such a time as the patient
takes a pill containing an orally available small molecule ligand. In the presence of the ligand, which is otherwise biologically inert, RTS is activated allowing expression of IL-12 at a specified therapeutic level and for a predetermined duration. RTS thereby regulates IL-12 expression to achieve a targeted clinically active level of IL-12 at the tumor while limiting broader systemic exposure and toxicities from the cytokine.
This ECC is also investigating the use of IL-12 in combination therapy with selected immunomodulators for solid tumors. This Multi-Inducible Cancer Immunomodulator, or MICI, program has multiple ongoing projects designed to identify proper cytokine candidates and develop vectors for cancer therapeutic applications. Three programs have been selected for development. Each is based on our multigenic expression platform, where two or more therapeutic proteins are expressed from a single DNA vector. Recent results from the MICI program have demonstrated successful expression of multigenic therapeutic proteins. Under both the DC-IL-12 and Ad-IL-12 programs, we are responsible for manufacturing the drug product and small molecule activator ligand. ZIOPHARM reimburses us for these manufacturing costs.
Pursuant to the ECC, ZIOPHARM received a license to our technologies within the field of cancer treatment in humans as defined more specifically in the ECC. We received 3,636,926 shares of ZIOPHARM’s common stock valued at $17.5 million as an upfront technology access fee. On October 24, 2012 upon the dosing of the first patient of a Phase II clinical trial, we received 3,636,926 shares of ZIOPHARM’s common stock valued at $18.3 million as milestone consideration, which is the sole milestone under this ECC. Subject to certain expense allocations, ZIOPHARM will pay us 50 percent of the quarterly net profits derived from the sale of products developed under the ECC.
Upon execution of this ECC, we purchased 2,426,235 shares of ZIOPHARM common stock with a value of $11.6 million, and we agreed to purchase up to $50.0 million of ZIOPHARM common stock in conjunction with securities offerings that may be conducted by ZIOPHARM in the future, subject to certain conditions and limitations. To date, we have purchased approximately $21.0 million of ZIOPHARM common stock in such securities offerings, and our remaining obligation on this purchase commitment is approximately $29.0 million."
Sentiment: Strong Buy
EntoGenetics founder David Brigham, Ph.D., a biochemist and geneticist, found a way to harvest high-strength spider silk from the well-established Chinese silkworm process, which dates back thousands of years. He genetically engineered a spider's silk-producing gene into silkworms.
His breakthrough company was featured in the financial publication Forbes in 2009 as one of the top 10 "Breakout Technology" firms.
Now that its silkworms are able to exude prolific quantities of spider silk, EntoGenetics has a corner on a fiber that's five times stronger than steel, two times stronger and ten times more elastic than Kevlar.
Those seductive statistics offer obvious military potential, for applications such as bulletproof vests, ropes and parachutes, as well as huge market potential for everything from the musical to the medical.
Though the company is not a university spin-out per se, it has a collaborative funding agreement and a visiting scientist arrangement with Marce Lorenzen, assistant professor of entomology at North Carolina State University.
Meanwhile, Super-Sensitive strings, used by many big-name musicians from fiddle-ripper Charlie Daniels to the late Yehudi Menuhin, might soon become popular for their unique arachnophonics – aka spider sound.
Sentiment: Strong Buy
Spider silk is already on the market? From businessweek -
EntoGenetics, Inc., a bio-engineering company, develops organic solutions. It offers spider silk. The company’s product is used in ballistic protection, clothing and apparel, medical, and sporting goods, as well as in industrial, automotive, and aerospace applications. EntoGenetics, Inc. was founded in 2007 and is based in Charlotte, North Carolina.
Their trademark names -
EGI offers BSS engineered for various applications, including OCTA™ (musical strings), FIGHTERweb™ (ballistic and protective gear), GossaMerge™ and Wisper™ (performance and fashion fabrics), REgener8™ (life sciences) and REcombin8™ (for composite applications).
Is KBLB playing catch up? Has any of you long term shareholders ever heard of this company? The knowledge on this board is far greater that what I have to offer, this just surprised me to read a company is supplying products to customers already.
Sentiment: Strong Buy
Spider silk sings in violin strings
Specialty Fabrics Review | March 2013
Super-Sensitive Musical String Co. will work with EGI to achieve the optimal composition of strength, stretch, tactile and tonal qualities in its violin strings to satisfy the demands of professional musicians.
Spider silk, a sticky protein combination that creates flexible threads with the tensile strength of steel, is a natural substance fascinating to material scientists, who have investigated possible applications in everything from ballistic protection to medical devices. The problem is that spiders don’t spin commercial quantities of fiber. Silkworms do, and EntoGenetics Inc. (EGI), a Charlotte, N.C., biotechnology firm partnering with North Carolina State University, used cross-species genetics to create a super-spinning silkworm, Bombyx mori. EGI launched its first business-to-business transaction in December, selling Biomimetic Spider Silk (BSS) to the Super-Sensitive Musical String Co., Sarasota, Fla., for use in high-performance violin strings.
“No, our silkworms do not have eight legs or fangs,” says Dr. David Brigham, founder and CEO of EGI. “But we do get them to spin their cocoons with the select qualities of spider silk and it can be done in mass quantity.” Brigham strung his own violin with BSS fiber as an experiment and noted the softer, more profound timbre of the sound. A concert violinist gave Brigham the thumbs-up shortly after playing on the spider silk strings, and a new application was born. EGI offers BSS engineered for various applications, including OCTA™ (musical strings), FIGHTERweb™ (ballistic and protective gear), GossaMerge™ and Wisper™ (performance and fashion fabrics), REgener8™ (life sciences) and REcombin8™ (for composite applications).